Clinical Trials

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.

Have you or your child been diagnosed with a blood disorder? If so, you (or they) may be able to participate in a clinical study where researchers are studying a type of infusion using cord blood. Participants can be of any age but must have a blood disorder diagnosed by their doctor. The study is taking place in locations in Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New York, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, Washington, D.C., West Virginia, and Wisconsin.

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.

Are you scheduled for a stem cell transplant with cord blood? This study will assess the safety and effectiveness of certain cord blood transplants. The study will help researchers learn the best methods for collecting, storing, and using cord blood in transplants. To participate in this study, you must have a disorder that compromises your body’s ability to make blood cells. This study is located in Bethesda, Maryland.

Does your developing baby have a heart defect? Have you had a stillborn baby? This study tests a new technology to measure fetal heart activity and find possible problems early. These problems include fetal arrhythmia and conduction disorders such as Brugada syndrome. To participate in this study, you must be at least 18 years old and pregnant, and have one of five high-risk complications of pregnancy: a fetus with a major congenital heart defect, hydrops, or gastroschisis; a previous unexplained stillbirth; or twins who share a placenta. This study is located in Madison and Milwaukee, Wisconsin.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Do you have a high-risk pregnancy? This study will investigate the use of a non-invasive scan called fetal magnetocardiography to detect potential problems in the fetus in five high-risk pregnancy conditions associated with stillbirth. The scan is normally used to look at fetal heart rhythms. To participate in this study, you must be at least 18 years old and pregnant with one of the following: having a stillbirth in a previous pregnancy, carrying identical twins, or having a fetus that has been diagnosed with major congenital heart disease, fetal hydrops, or fetal gastroschisis. This study takes place in Madison and Milwaukee, Wisconsin.

Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.

Are you an adult who receives long-term red blood cell transfusion therapy for sickle cell disease? This 3-month study tests whether donated blood that is more than 30 days old leads to more infections in people with sickle cell disease than blood that is less than 10 days old. Some hospitals around the United States have requirements regarding the age of donor blood. This research aims to inform new evidence-based policies on the age and use of donor blood in people with sickle cell disease that rely on blood transfusions. To participate in this study, you must be between 16 and 45 years old, have sickle cell disease, and be receiving long-term red blood cell transfusion therapy. This study takes place in Atlanta, Georgia; Chapel Hill, North Carolina; and Milwaukee, Wisconsin.

Are you or your child between the ages of 3 and 21 and experiencing pain episodes? This study tests a treatment called arginine therapy for pain episodes in children with sickle cell disease. Researchers are investigating how safe and effective this treatment is, as well as how arginine is metabolized in the body and its effects on cells. To participate in this study, you or your child must have sickle cell disease and pain that requires medical attention. This study takes place in multiple locations in the United States.